Dr. med. Joachim Köchling

Dr. med. Joachim Köchling

Facharzt für Kinder- und Jugendmedizin
Kinder-Hämatologie und –Onkologie
Ernährungsmedizin, Notfallmedizin
Persönliche Daten:

Dr. med. Joachim Köchling
Geboren in Goch 3.8.1960

Familie
Verheiratet seit 1996 mit Katrin Eilts-Köchling,
4 Kinder: 1998 Esther, 2000 Judith, 2002 Deborah, 2004 Mirjam

Interessensgebiete
Meine Familie, Kunst, Konzerte, Theater, Kino, Fotographie, Aquaristik, Reisen, Mountain Bike, Kajak, Wandern, Schwimmen, Langlaufski.

 
Berufliche Vita
1980 Abitur in Wolfhagen
1980 – 1981 Grundwehrdienst als Sanitäter in Marburg und Wolfhagen
1982 – 1983 Studium der Biochemie an der Freien Universität Berlin
1983 – 1987 Studium der Medizin an der Freien Universität Berlin
1987 – 1988 Studium der Medizin in Großbritannien
– University of Edinburgh
– University London (Guy’s und St. Thomas’s Medical School)
1988 – 1991 Studium der Medizin an der Freien Universität Berlin
1993 Ärztliche Approbation
1993 Promotion an der Freien Universität Berlin:
„Pharmakokinetik und Pharmakodynamik von rekombinantem humanem Erythropoetin bei Hämodialysepatienten“
2005 Zusatzbezeichnung Notfallmedizin
2009 Facharztprüfung: Facharzt für Kinder- und Jugendmedizin
2012 Prüfung des Schwerpunktbereichs Päd. Hämatologie u. Onkologie
2015 Zusatzbezeichnung Pädiatrische Ernährungsmedizin
Arbeitsverhältnisse
1992 – 1994 Abteilung für Kinderchirurgie, Freie Universität Berlin
1994 – 1996 Tufts University and New England Medical Center (NMEC), Boston, USA
1997 – 2000 Klinik für Pädiatrie, Charité, Campus Virchow-Klinikum, Berlin
2001 – 2001 Abteilung für Innere Medizin, Stadtkrankenhaus Bad Arolsen
2002 – 2003 Kinderklinik der Eberhard Karls Universität Tübingen
2003 – 2005 Abteilung für Innere Medizin, Stadtkrankenhaus Bad Arolsen
2006 –2011 Klinik für Kinder- und Jugendmedizin, UKSH, Campus Lübeck
2012 – 2015 Arbeit als Notarzt und Honorararzt
2015 – dato Praxis für Kinder- und Jugendmedizin in Bad Segeberg
Preise / Nominierungen
1994 – 1996 Ausbildungsstipendium der Deutschen Forschungsgemeinschaft
1996 Ausbildungsstipendium des NMEC, Tufts University Boston, USA
1997 – 2000 Forschungsförderung der Charité
2002 – 2004 Forschungsstipendium der Wilhelm Sander Stiftung
2003 Forschungsförderung der Universitätskinderklinik Tübingen
2005 – 2010 Forschungsstipendium der Deutschen José Carreras Leukämie-Stiftung
2008 – 2010 Forschungsförderung durch die Lübeck-Hilfe für krebskranke Kinder
2009 – 2010 Forschungsförderung der Universitätskinderklinik Lübeck
Publikationen
Brockmöller J, Köchling J, Weber W, Looby M, Roots I, Neumayer HH (1992) The pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in hemodialysis patients. Br J Clin Pharmacol 34(6): 499-508

Köchling J, Pistor G, Märzhäuser-Brands S, Nasir R, Lanksch WR (1996) The Currarino Syndrome – Heriditary transmitted syndrome of anorectal, sacral and presacral anomalies. Case report and review of the literature. Eur J Pediatr Surg 6(2): 114-119

Köchling J, Curtin PT, Madan A (1998): Regulation of human erythropoietin gene induction by upstream flanking sequences in transgenic mice. Br J Haematol 103(4): 960-968

Korte A, Möricke A, Beyermann B, Köchling J, Taube T, Kebelmann-Betzing C, Henze G, Seeger K (1999) Extensive alternative splicing of interleukin-7 in malignant hematopoietic cells: Implication of distinct isoforms in modulating IL-7 activity. J Interferon Cytokine Res 19(5): 495-503

Seeger K, Buchwald D, Taube T, Peter A, von Stackelberg A, Schmitt G, Köchling J, Henze G (1999) TEL-AML1 positivity in relapsed B cell precursor acute lymphoblastic leukemia in childhood. Leukemia 13(9): 1469-1470

Korte A, Köchling J, Badiali L, Eckert C, Andreae J, Geilen W, Kebelmann-Betzing C, Taube T, Wu S, Henze G, Seeger K (2000) Expression analysis and characterization of alternatively spliced transcripts of human IL-7Ra chain encoding two truncated receptor proteins in relapsed childhood ALL. Cytokine 12(11): 1597-1608

Einsiedel HGV, Taube T, Beyermann B, Dragon S, Möricke A, Kebelmann-Betzig C, Köchling J, Henze G, Seeger K (2001) Absence of mutations in the CDKN2 binding site of CDK4 in childhood acute lymphoblastic leukemia. Leuk Lymphoma 40(3-4): 413-417

Kebelmann-Betzing C, Körner G, Badiali L, Buchwald D, Möricke A, Korte A, Köchling J, Wu S, Kappelmeier D, Oettel K, Henze G, Seeger K (2001) Characterization of cytokine, growth factor receptor, costimulatory and adhesion molecule expression pattern of bone marrow blasts in relepsed childhood B-cell precursor ALL. Cytokine 13(1): 39-50

Köchling J, Kabasiyan M, Reis A (2001) Spectrum of mutations and genotype-phenotype analysis in Currarino Syndrome. Eur J Hum Genet 9(8): 599-605

Köchling J, König Merediz SA, Stripecke R, Buchwald D, Korte A, von Einsiedel HG, Sack F, Henze G, Seeger K, Wittig B, Schmidt M (2003) Protection of mice against Ph+ acute lymphoblastic leukaemia by cell-based vaccination using non-viral, minimalistic expression vectors and immunomodulatory oligonucleotides. Clin Cancer Res 9(8): 3142-3149

Maia AT, Koechling J, Corbett R, Metzler M, Wiemels JL, Greaves M (2004) Protracted postnatal natural histories in childhood leukemia. Genes Chromosomes Cancer 39(4): 335-340

Riebel T, Kochling J, Scheer I, Oellinger J, Reis A (2004) Currarino syndrome: Variability of imaging findings in 22 moleculargenetically identified HLXB9 mutation patients from five families. Rofo 176(4): 564-569

Zuna J, Ford AM, Peham M, Patel N, Saha V, Eckert C, Köchling J, Panzer-Grümayer R, Trka J, Greaves M (2004) TEL deletion analysis supports a novel view of relapse in childhood acute lymphoblastic leukemia. Clin Cancer Res 10(16): 5355-5360

Köchling J, Freitag HJ, Bollinger T, Herz A, Sperner J (2008) Neuroborreliosis with Lymphocytic Meningitis and Unilateral Trigeminal Nerve Palsy: Follow Up of MRI and Serological Findings. Eur J Paediatr Neurol 12(6): 501 – 504

Köchling J, Prada JJ, Bahrami M, Stripecke R, Seeger K, Henze G, Wittig B, Schmidt M (2008) Anti-tumor effect of DNA-based vaccination and dSLIM immunomodulatory molecules in mice with Ph+ acute lymphoblastic leukaemia. Vaccine 26(36): 4669-4675

Köchling J, Rott Y, Arndt S, Marschke C, Schmidt M, Wittig B, Kalies K, Westermann J, Henze G (2012) Prevention and synergistic control of Ph+ ALL by a DNA vaccine and 6-mercaptopurine. Vaccine 30(41): 5949-5955

Köchling J,  Schmidt M, Rott Y, Sagner M, Ungefroren H, Wittig B, Henze G (2013)  Can anthocyanins improve maintenance therapy of Ph+ acute lymphoblastic leukemia?  Eur J Haematol 90: 291–300.

Veröffentlichte Kurzfassungen

Köchling J, Hatch II SL, Madan A, Curtin PT (1995) Desoxyribonuclease I hypersensitive site in erythropoietin transgenic mice suggests the location of a regulatory element. Blood 86: 312a

Köchling J, Curtin PT, Madan A (1997) Mapping the kidney-specific inducible element upstream of the human erythropoietin gene. Blood 90: 309a

Seeger K, Buchwald D, Beyermann B, Adams HP, Köchling J, Schmid HJ, Niemeyer C, Janka G, Henze G, for the BFM relapse study group (1997) TEL-AML1 fusion transcript in relapsed childhood acute lymphoblastic leukemia (ALL). Blood 90: 560a

Köchling J, Madan A, Curtin PT (1998) A new functional HIF-1 binding site upstream of the human erythropoietin gene. Blood 92: 208a

Seeger K, Kreuzer KA, Schmidt CA, Buchwald D, Lass U, Schmitt G, Taube T, Kochling J, Beyermann B, Huhn D, Henze G (1998) Novel 5’ exonuclease-based real time PCR assay for the detection of TEL-AML1 fusion in childhood acute lymphoblastic leukemia (ALL). Blood 92: 392a

Seeger K, Buchwald D, Köchling J, Beyermann B, Möricke A, Schmitt G, Hanel C, Götze G, Henze G (1998) CBFA2/ETV6 fusion in ETV6/CBFA2 positive childhood ALL. Medical and Pediatric Oncology 31: 295

Curtin PT, Wang Z, Madan A, Köchling J (1999) An hypoxia-inducible regulatory element is present 9.2 kb upstream of the human erythropoietin gene. Blood 94: 261a

Köchling J, König Merediz SA, Sack F, Stripecke R, Buchwald D, Badiali, L, Schmid H, Henze G (1999) Gene therapy of PH+ ALL by DNA immunization and leukemic cell vaccines in a syngeneic mouse model. Blood 94: 411b

Korte A, Seeger K, Möricke A, Beyermann B, Köchling J, Taube T, Kebelmann-Betzing C, Henze G (1999) High diversity of splicing-derived interleukin-7 isoforms in acute lymphoblastic leukemia. Haematologica 84: 8a

Kebelmann-Betzing C, Schmitt G, Badiali L, Buchwald D, Möricke A, Köchling J, Wu S, Korte A, Schmid H, Henze G, Seeger K (1999) Cytokine, growth factor receptor, costimulatory and adhesion molecule expression pattern in relapsed childhood B-cell precursor ALL bone marrow blasts. Blood 94: 220b

Korte A, Badiali L, Köchling J, Schmid H, Geilen W, Eckert C, Kebelmann-Betzing C, Henze G, Seeger K (1999) IL-7Ra expression of leukemic cells and identification of two alternatively spliced transcripts encoding different truncated IL-7Ra proteins in childhood ALL. Blood 94: 72a

Seeger K, Kreuzer KA, Buchwald D, Taube T, Lass U, Schmitt G, Köchling J, Schmidt CA, Henze G (1999) Novel 5’exonuclease-based real-time PCR assay for the detection of TEL-AML1 fusion in childhood ALL. Klin Pädiatr 211: 377

Seeger KH, Wu S, Köchling J, Taube T, Geilen W, Buchwald D, Schmid HJ, Henze G (1999) Bone marrow stromal and lymphoblastic cells show distinct cytokine gene expressions and differential responses to SCF and IL-7 in childhood ALL. Blood 94: 72a

Curtin PT, Wang Z, Köchling J (2000) Conserved sequences upstream of the mouse erythropoietin gene suggests the presence of an additional hypoxia-responsive regulatory element. Blood 96: 131b

Köchling J, König Merediz SA, Wittig B, Stripecke R, Korte A, Seeger K, Taube T, Wu S, Schmid H, Henze G (2000) In-vivo transfection of murine skin with a novel expression vector encoding BCR-ABL breakpoint specific peptides prevents Ph+ ALL. Blood 96: 800a

Wu S, Andreae J, Korte A, Hanel C, Köchling J, Schmid H, Henze G, Seeger K (2000) Prednisolone inhibits the expression of cytokines and surface adhesion molecules of human bone marrow stromal cells in childhood ALL. Blood 96: 169b

Köchling J, Bahrami M, Stripecke R, Wittig B, Henze G, Seeger K, Schmidt M (2003) Optimization of DNA vaccine strategies protects mice against syngeneic Ph+ ALL. Blood 102: 746a

Riebel T, Köchling J, Scheer I, Oellinger H, Reis A (2003) Currarino triad: variability of immaging findings in 23 moleculargenetically identified patients. Pediatric Radiology 33 (Suppl 2): S30

Zuna J, Ford A, Peham M, Patel N, Saha V, Eckert C, Köchling J, Panzer-Grumayer R, Trka J, Greaves M (2003) Recurrence of TEL/AML1-positive ALL – Relapse or a new disease? Blood 102: 140a

Köchling J, Prada J, Bahrami M, König-Merediz SA, Stripecke R, Seeger K, Henze G, Wittig B,  Schmidt M (2006) BCR-ABL specific sequences are required to prevent Ph+ acute lymphoblastic leukemia in syngeneic mice by DNA vaccination. Blood 108: 931a

Köchling J, Rott Y, Arndt S, Green J, Anderson D, Langer R, Stripecke R, Wittig B, Schmidt M (2007) Prevention of Ph+ acute lymphoblastic leukemia by nanoparticulate delivery of a DNA vaccine in syngeneic mice. Blood 110: 5135a

Köchling J, Rott Y, Arndt S, Green J, Anderson D, Langer R, Stripecke R, Schmidt M, Henze G, Bucsky P (2008) Prevention of Ph+ acute lymphoblastic leukaemia by DNA vaccination using a non-viral vector system and nanoparticle delivery. Eur J Paed 167: 371

Rott Y, Arndt S, Green J, Anderson D, Stripecke R, Schmidt M, Wittig B, Köchling J (2008) Opimization of a BCR-ABL specific DNA vaccine against Ph+ ALL using a nonviral vector system and nanoparticle delivery. Blood 112: 4625

Rott Y, Arndt S, Green J, Stripecke R, Wittig B, Schmidt M, Köchling J (2009) CD8+ T cells and natural killer cells are essential for the immunization by a BCR-ABL-specific DNA vaccine against Ph+ ALL. Mol Ther 17: S155

Rott Y, Arndt S, Marschke C, Stripecke R, Wittig B, Schmidt M, Köchling J (2009) Synergism between Imatinib mesylate and a BCR-ABL-specific DNA vaccine against pre-established Ph+ acute lymphoblastic leukemia in syngeneic mice. Blood 114: 1201

Rott Y, Köchling J (2010) Synergismus von BCR-ABL spezifischer DNA-Vakzine und Imatinib als Rezidivprophylaxe bei Ph+ akuter lymphoblastischer Leukämie im syngenen Mausmodell. Pädiatrie hautnah 22: 266-267, P43

Rott Y, Schmidt M, Wittig B, Herting E, Köchling J (2010) Synergism between chemotherapy with 6-mercaptopurine and DNA vaccination against Ph+ acute lymphoblastic leukemia in syngeneic mice. Blood 116: 1338

Rott Y, Sagner M, Ungefroren H, Schmidt M, Wittig B, Herting E, Köchling J (2010) Antileukemic efficacy of anthocyanins in-vitro and in-vivo and in combination with a DNA vaccine against Ph+ acute lymphoblastic leukemia. Blood 116: 1339

Rott Y, Arndt S, Marschke C, Lauten M, Schmidt M, Wittig B, Kalies K, Westermann J, Köchling J (2011) Highly efficient treatment of Ph+ acute lymphoblastic leukemia with a DNA vaccine and 6-mercaptopurine in mice. Mol Ther 19: S195

Rott Y, Lauten M, Ungefroren H, Sagner M, Schmidt M, Wittig B, Köchling J (2011) Berry extract enhances a leukemia specific DNA vaccine in the treatment of minimal residual disease in mice with Ph+ ALL. Mol Ther 19: S195-196

[top]